Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 1×
“Bilirubin umol/L (4-20) Albumin g/L (36-47)”
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Cited by
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
“If there is no response to corticosteroids within 2–3 days, mycophenolate mofetil should be added at 1000 mg twice daily [IV–V, B] [34].”
BackgroundToxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
A review of cancer immunotherapy toxicity
Kennedy, L. B., & Salama, A. K. S. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,364
Haanen, J., Obeid, M., Spain, L., Carbonnel, F., Wang, Y., Robert, C., Lyon, A. R., Wick, W., Kostine, M., Peters, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.001 · Cited by 1,311
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review
Friedman, C. F., Proverbs-Singh, T. A., & Postow, M. A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1051 · Cited by 802
Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704
“57 case reports with at least one irAE [26, 36–91].”
BackgroundThompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Self-citationCharacterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
De Martin, E., Michot, J.-M., Papouin, B., Champiat, S., Mateus, C., Lambotte, O., Roche, B., Antonini, T. M., Coilly, A., Laghouati, S., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.033 · Cited by 520
Voskens, C. J., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 468
Managing Immune Checkpoint-Blocking Antibody Side Effects
Postow, M. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.76 · Cited by 403
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Ipilimumab and Its Toxicities: A Multidisciplinary Approach
Fecher, L. A., Agarwala, S. S., Hodi, F. S., & Weber, J. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0483 · Cited by 320
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.021 · Cited by 293
Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation
Peeraphatdit, T. (., Wang, J., Odenwald, M. A., Hu, S., Hart, J., & Charlton, M. R. (2020) · Hepatology · doi:10.1002/hep.31227 · Cited by 264
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
Kim, K. W., Ramaiya, N. H., Krajewski, K. M., Jagannathan, J. P., Tirumani, S. H., Srivastava, A., & Ibrahim, N. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9939-6 · Cited by 235
Kidney injuries related to ipilimumab
Izzedine, H., Gueutin, V., Gharbi, C., Mateus, C., Robert, C., Routier, E., Thomas, M., Baumelou, A., & Rouvier, P. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0092-7 · Cited by 171
Tay, R. Y., Blackley, E., McLean, C., Moore, M., Bergin, P., Gill, S., & Haydon, A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.253 · Cited by 119
“ATGAM has been successfully used to treat at least two cases of severe ipilimumab-induced hepatotoxicity (Chmiel et al, 2011; Ahmed et al, 2015).”
Liu, Z., Zhu, Y., Xie, H., & Zou, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077468 · Cited by 77
Berry, P., Kotha, S., Zen, Y., Papa, S., El Menabawey, T., Webster, G., Joshi, D., & Heneghan, M. (2023) · Liver International · doi:10.1111/liv.15340 · Cited by 47
Metadata
- Authors
- Chmiel, K. D., Suan, D., Liddle, C., Nankivell, B., Ibrahim, R., Bautista, C., Thompson, J., Fulcher, D., & Kefford, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-03-20
- Volume
- 29
- Issue
- 9
- Pages
- e237-e240
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2096511276
- Cited by
- 164
- References
- 2
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.